Review top news and interview highlights from the week ending October 27, 2023.
Ophthalmology
Latest News
Advertisement
CME Content
Advertisement
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The company expects that pivotal ATMOSPHERE and ASCENT trials will support a BLA filing in 2024 for wet AMD, while the AAVIATE trial evaluates the therapy in diabetic retinopathy.
The associate professor of ophthalmology at Harvard Medical School discussed investigational corneal transplant therapy.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The associate professor of clinical ophthalmology at University of Miami discussed his experience using the gene therapy in a compassionate use program.
Review top news and interview highlights from the week ending October 6, 2023.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The senior partner at Retina Vitreous Associates Medical Group discussed efficacy and safety data from the phase 2 AAVIATE trial.
Review top news and interview highlights from the week ending September 29, 2023.
The adjunct clinical assistant professor, ophthalmology, Keck School of Medicine, University of Southern California discussed new data from the ALTITTUDE trial.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The phase 1/2 trial is opening its second phase of recruitment after being well-tolerated in the first 4 patients and demonstrating some vision improvements.
NFS-05 is an ophthalmic injection that uses an AAV vector to deliver the OPA1 gene to retinal ganglion cells.
The chairman, chief executive officer, and cofounder of Ocugen discussed unmet needs within retinitis pigmentosa and the potential of OCU400 gene therapy.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Among 12 patients evaluable for efficacy, 10 patients experienced stabilization or improvement from baseline in BCVA in their treated eyes.
Opus Genetics plans to add a pediatric cohort to the phase 1/2 trial once safety is established in adults.
Review top news and interview highlights from the week ending September 15, 2023.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Novartis stated that the decision was made in light of a recommendation from an independent data monitoring committee.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
It was the first time the Eye Center treated a patient with a gene therapy.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Advertisement
Advertisement
Trending on CGTlive®
1
Integrating Gene Therapy into Clinical Care for Sickle Cell Disease
2
Hematology-Oncology Immunotherapy Highlights at ASH 2025
3
Deevyashali Parekh, MBBS, on Evaluating CAR-T in Patients With Multiple Myeloma and Renal Failure
4
FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma
5
